Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: J Allergy Clin Immunol. 2008 Oct 30;122(6):1127–1135.e8. doi: 10.1016/j.jaci.2008.09.029

Figure 1. Enrollment and outcome.

Figure 1

Treatment failure rates were comparable across treatment groups (p=0.5). Dropouts were more frequent in the montelukast group (12.6%) compared to budesonide (5.2%) and the conventional therapy group (2.1%) (p=0.04 across groups) and were predominantly due to loss to follow-up.